onr:"swepub:oai:gup.ub.gu.se/58448"
Search: onr:"swepub:oai:gup.ub.gu.se/58448" > The oral direct thr...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Hellgren, Margareta,1947Gothenburg University,Göteborgs universitet,Institutionen för kvinnors och barns hälsa, Avdelningen för obstetrik och gynekologi,Institute for the Health of Women and Children, Dept of Obstetrics and Gynaecology (author)
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation
- Article/chapterEnglish2005
Publisher, publication year, extent ...
- Wiley,2005
Numbers
- LIBRIS-ID:oai:gup.ub.gu.se/58448
- https://gup.ub.gu.se/publication/58448URI
- https://doi.org/10.1111/j.1471-0528.2004.00494.xDOI
Supplementary language notes
- Language:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- OBJECTIVE: To determine the excretion of the oral direct thrombin inhibitor (oral DTI), ximelagatran, and its active form, melagatran, in human milk, and to thus evaluate the potential exposure of breastfed infants to melagatran. DESIGN: An open, single dose, single centre study. SETTING: Department of Antenatal Care, Primary Health Care South Bohuslan and Institute for the Health of Women and Children, Goteborg University, Sweden. SAMPLE: Seven healthy Caucasian breastfeeding women who were at least two months postpartum were studied. METHODS: The concentrations of ximelagatran, its two intermediates, and melagatran were determined using liquid chromatography-mass spectrometry, with the limit of quantification of 2 nmol L(-1) for human milk and 10 nmol L(-1) for plasma concentrations. MAIN OUTCOME MEASURES: Concentrations of ximelagatran, its intermediates and melagatran were measured in breast milk over 72 hours, and in plasma over 12 hours, after a single oral 36 mg dose of ximelagatran. RESULTS: Neither ximelagatran nor its intermediates were detected in human breast milk. Only trace amounts of melagatran were detected. The mean cumulative amount of melagatran excreted into breast milk over the 72-hour period after dosing with oral ximelagatran was 0.00091% of the administered dose of ximelagatran. Ximelagatran was well tolerated, with no clinically relevant changes in laboratory variables or vital signs. CONCLUSIONS: Trace levels of melagatran are excreted in human breast milk following administration of the oral DTI ximelagatran. The exposure of breastfed infants to melagatran appears to be low and is therefore unlikely to be of clinical concern.
Subject headings and genre
- Administration
- Oral
- Adult
- Anticoagulants/administration & dosage/*pharmacokinetics
- Azetidines/administration & dosage/*pharmacokinetics
- Benzylamines
- *Breast Feeding
- Female
- Glycine/*analogs & derivatives/*analysis/metabolism
- Humans
- Lactation
- Milk
- Human/*chemistry
- Postpartum Period
- Puerperal Disorders/prevention & control
- Thrombin/*antagonists & inhibitors
- Thromboembolism/prevention & control
- Venous Thrombosis/prevention & control
Added entries (persons, corporate bodies, meetings, titles ...)
- Johansson, S (author)
- Eriksson, U G (author)
- Wahlander, K (author)
- Göteborgs universitetInstitutionen för kvinnors och barns hälsa, Avdelningen för obstetrik och gynekologi (creator_code:org_t)
Related titles
- In:Bjog: Wiley112:5, s. 579-83
- In:BJOG: An International Journal of Obstetrics & Gynaecology: Wiley112:5, s. 579-831470-03281471-0528
Internet link
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hellgren, Margar ...
- Johansson, S
- Eriksson, U G
- Wahlander, K
- Articles in the publication
- Bjog
- BJOG: An Interna ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
